Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are correct. If they had a viable product, financiers would be beating a path to their door. Or they would be pursuing partners or financing. Neither is happening. Add to that, not one reputable/knowledgeable bio analyst is following the stock. These should be red flags. Instead we have a sizable group of obsessed followers, who have convinced themselves the stock is a goldmine. They literally spend day and night convincing each other of the huge profits they will make. This obsession has led to over investment, in a highly risky stock. The future could be bleak for many.
The recent appointments have not been from the Alzheimers arena, this is significant.
You are correct Maxim is "pumper to the scams."
That is sometimes a good strategy also. :)
Rumors leaking out that Missling has been sitting on bad news for weeks. Large drop on share price coming soon.
If it slips below $1.00, it will,be there for a long, long time:(
Thanks, good to know!
Anyone know how many of those preferred shares exist with a conversion rate of 1000 common for each single preferred share? That is crazy!!
You are correct. The stock has been subject to manipulation since the original announcement of the reverse merger. The nature of the merger, as well as the benefit to then STEM share holders, was totally exaggerated. Phony posts claiming the new stock would soon be $20.00, were everywhere. The company had nothing to do with this, it was all outside forces. attempting to manipulate the small float. Most buyers knew little or nothing about the company. MBOT does have viable products but will need production and distribution help. A partnership looks likely down the road.
Much of the down draft is still those that bought way too high, a few days back. Stock deals to raise money to move forward, is not unusual, in a small company. The question is...is their product viable. Likely it is but that is quite a ways off.
People selling what they bought for $4-5 bad move it will come back. A buy under $2.50.
This will drop quickly, as it has in the past. They are a long, long way from any decent sales.
Time to get in for the next run-up. Any where below .35 will do it
The huge jump in volume, on the news, is important. It went from 11,000 shares traded all day, to an excess of 10 million shares traded on the news. This shows a huge interest, in a small stock. Because of the tiny float, it will jump up and down quickly. Right now, anything in the low $6.00 area looks good. All it needs, is any type of licensing agreement or other news and it will shoot up again, very fast.
Here come the shareholder lawsuits.
A.83. B.8301 extremely tight spread.
I agree, someone is buying all available around the .83 cent area. Is the 10.1 m shares outstanding, shown on yahoo accurate? Oft times yahoo is not correct.
Agreed, when the smoke settles, the stock will come back to well above a buck.
Agree on the $1.00 down the road. so buy 12000 shares now, make $2k down the road.
Short term yes, a buy. I see low $1.00 range bu next week. A 10m share float, 17m traded so far today. That's healthy.
David DeWalt out as FireEye CEO, Kevin Mandia to take over
FireEye Loss Widens Sharply Despite Higher Revenue, Billings ..Wall Street Journal
Earnings don't look good off $2.00 after hours.
The 39000 may have been a late report from the regular session. Something is going on, sudden rise starting yesterday, perhaps up coming earnings?
30 minutes after close, an after hours buy of 39,000 shares or a $415,000 investment unusual for AH.
Yep, the float is so small it moves even on tiny volume. The company is going to do an investor presentation in the near future, it may spurn some investor interest.
The company offers a 700,000 share block at $5.00 a share and the stock jumps to 8.00?? Crazy!!
Despite some good news, it continues to slide downhill. $10 soon ?
Where are all the former STEM shareholders who were going to get rich on this one? Nothing to cheer about lately?
A tiny float causes the stock to jump up and down quickly, even on a small buy or sell, don't be fooled.
Every thing AF says below, is basically true. The results produced by AVXL, to this point, can not be trusted, without much further confirmation. He is not involved in some vast conspiracy to short the stock, just speaking the truth.
Bad clinical trials produce bad data, and Anavex is conducting a garbage study.
The only way to produce credible data in Alzheimer's is to conduct randomized, double-blind, placebo-controlled studies. One group of patients is randomized to receive a drug, the other group of patients received a placebo. Neither the patients nor their doctors know which arm of the study they're in. These studies need to run for at least one year because it takes that long to detect meaningful changes in memory, cognition and functions of daily living of patients.
Only those who formally held STEM shares, have to wait for regulators ok on the transfer. Those issued new shares, directly, are free to sell or buy more, also those who bought today or yesterday are free to sell as well.
That's after the RS only. You need to figure in STEM shareholders get only 5% of existing MBOT shares
Could be longer than 3 days has to get regulators ok. With a 9 to 1 reverse split and former STEM share holders getting 5% of the new shares to split amongst them, expect a substantial loss.
Read the last paragraph carefully.
Following the completion of the merger and one–for-nine reverse stock split, there are approximately 39 million shares of common stock outstanding. Under the terms of the merger agreement with StemCells, the shareholders of Microbot Medical, and certain advisors and consultants with respect to the merger, received shares of StemCells common stock representing approximately 95% of the outstanding shares of StemCells calculated on a fully diluted basis. Stockholders of StemCells prior to the merger have retained approximately 5% of the company.
Whom ever it is. I expect it would be of interest to those on the board.
Yes, this Sunday, the advertisement did not say what study. I figured I'd tune in and be surprised. :)
60 Minutes, CBS Sunday night, report on new Alzheimer's study.
Lilly failing, is only a good sign for AVXL, If you enjoy a good Cinderella story :)
You aren't one of their investors, in any meaningful way, unless you want to buy the new stock after the merger. Again read the merger agreement, come to your own conclusions.